These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 25266748)
61. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC]. Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219 [TBL] [Abstract][Full Text] [Related]
62. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer]. Li J Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800 [No Abstract] [Full Text] [Related]
63. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study. Chu E Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190 [No Abstract] [Full Text] [Related]
65. Liver metastasis from colonic adenocarcinoma presenting as nephrolithiasis: computed tomography findings. Abu-Ghanem S; Novik EF; Abu-Ghanem Y; Man S; Shelef I Isr Med Assoc J; 2011 Oct; 13(10):638-9. PubMed ID: 22097237 [No Abstract] [Full Text] [Related]
66. [Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma]. Braun-Falco M; Holtmann C; Lordick F; Ring J Hautarzt; 2006 Aug; 57(8):701-4. PubMed ID: 15991047 [TBL] [Abstract][Full Text] [Related]
67. Acneiform eruption following molecular targeted chemotherapy. Vaccaro M; Barbuzza O; Pollicino A; Guarneri C Intern Med J; 2011 Apr; 41(4):361-2. PubMed ID: 21507168 [No Abstract] [Full Text] [Related]
68. Re: Cetuximab therapy and symptomatic hypomagnesemia. Altundag K; Altundag O; Baptista MZ; Turen S; Atik MA J Natl Cancer Inst; 2005 Dec; 97(23):1791-2. PubMed ID: 16333039 [No Abstract] [Full Text] [Related]
69. Administration of anti-EGFR therapy: a practical review. Khoukaz T Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):20-7. PubMed ID: 16616283 [TBL] [Abstract][Full Text] [Related]
70. Antitumor activity in metastatic disease does not predict efficacy in the adjuvant setting. Segal NH; Saltz LB JAMA; 2012 Apr; 307(13):1431-2. PubMed ID: 22474207 [No Abstract] [Full Text] [Related]
71. Nimotuzumab: evidence of clinical benefit without rash. Allan DG Oncologist; 2005 Oct; 10(9):760-1. PubMed ID: 16249358 [No Abstract] [Full Text] [Related]
72. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. Hollywood E Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862 [TBL] [Abstract][Full Text] [Related]
76. Epistaxis secondary to panitumumab in a patient with colon cancer. Kornreich DA; Saif MW Anticancer Res; 2012 Nov; 32(11):4983-5. PubMed ID: 23155268 [TBL] [Abstract][Full Text] [Related]
77. A rare but severe pulmonary side effect of cetuximab in two patients. Achermann Y; Frauenfelder T; Obrist S; Zaugg K; Corti N; Günthard HF BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22843749 [TBL] [Abstract][Full Text] [Related]
78. Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis. Pointreau Y; Commins SP; Calais G; Watier H; Platts-Mills TA J Clin Oncol; 2012 Jan; 30(3):334; author reply 335. PubMed ID: 22162592 [No Abstract] [Full Text] [Related]
79. Panitumumab as a possible cause of hematospermia: what is the mechanism? Karatas F; Sahin S; Imamoglu GI; Altinbas M Future Oncol; 2015; 11(24):3229-31. PubMed ID: 26562760 [No Abstract] [Full Text] [Related]